JTX 2011

Drug Profile

JTX 2011

Alternative Names: JTX-2011

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator Jounce Therapeutics
  • Class Antineoplastics; Cell therapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action Inducible T-cell co-stimulator protein agonists; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 07 Sep 2016 Phase-I/II clinical trials in Solid tumours (Combination therapy) in USA (unspecified route)
  • 07 Sep 2016 Phase-I/II clinical trials in Solid tumours in USA (unspecified route)
  • 19 Jul 2016 Jounce Therapeutics and Celgene Corporation enter a collaboration for development of cancer immunotherapies including JTX 2011
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top